Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold.

Bolton SA, Sutton JC, Anumula R, Bisacchi GS, Jacobson B, Slusarchyk WA, Treuner UD, Wu SC, Zhao G, Pi Z, Sheriff S, Smirk RA, Bisaha S, Cheney DL, Wei A, Schumacher WA, Hartl KS, Liu E, Zahler R, Seiler SM.

Bioorg Med Chem Lett. 2013 Sep 15;23(18):5239-43. doi: 10.1016/j.bmcl.2013.06.028. Epub 2013 Jun 20.

PMID:
23927973
2.

Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.

Shi Y, Li C, O'Connor SP, Zhang J, Shi M, Bisaha SN, Wang Y, Sitkoff D, Pudzianowski AT, Huang C, Klei HE, Kish K, Yanchunas J Jr, Liu EC, Hartl KS, Seiler SM, Steinbacher TE, Schumacher WA, Atwal KS, Stein PD.

Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9. doi: 10.1016/j.bmcl.2009.10.084. Epub 2009 Oct 23.

PMID:
19896847
3.

Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.

Shi Y, Zhang J, Shi M, O'Connor SP, Bisaha SN, Li C, Sitkoff D, Pudzianowski AT, Chong S, Klei HE, Kish K, Yanchunas J Jr, Liu EC, Hartl KS, Seiler SM, Steinbacher TE, Schumacher WA, Atwal KS, Stein PD.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4034-41. doi: 10.1016/j.bmcl.2009.06.014. Epub 2009 Jun 13.

PMID:
19541481
4.

Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.

Shi Y, Sitkoff D, Zhang J, Klei HE, Kish K, Liu EC, Hartl KS, Seiler SM, Chang M, Huang C, Youssef S, Steinbacher TE, Schumacher WA, Grazier N, Pudzianowski A, Apedo A, Discenza L, Yanchunas J, Stein PD, Atwal KS.

J Med Chem. 2008 Dec 11;51(23):7541-51. doi: 10.1021/jm800855x.

PMID:
18998662
5.

Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.

Schumacher WA, Seiler SE, Steinbacher TE, Stewart AB, Bostwick JS, Hartl KS, Liu EC, Ogletree ML.

Eur J Pharmacol. 2007 Sep 10;570(1-3):167-74. Epub 2007 Jun 5.

PMID:
17597608
6.

Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.

Shi Y, Zhang J, Stein PD, Shi M, O'Connor SP, Bisaha SN, Li C, Atwal KS, Bisacchi GS, Sitkoff D, Pudzianowski AT, Liu EC, Hartl KS, Seiler SM, Youssef S, Steinbacher TE, Schumacher WA, Rendina AR, Bozarth JM, Peterson TL, Zhang G, Zahler R.

Bioorg Med Chem Lett. 2005 Dec 15;15(24):5453-8. Epub 2005 Oct 5. Erratum in: Bioorg Med Chem Lett. 2006 Mar 1;16(5):1449.

PMID:
16213711
7.

Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.

Sutton JC, Bolton SA, Davis ME, Hartl KS, Jacobson B, Mathur A, Ogletree ML, Slusarchyk WA, Zahler R, Seiler SM, Bisacchi GS.

Bioorg Med Chem Lett. 2004 May 3;14(9):2233-9.

PMID:
15081015
8.

Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase.

Bisacchi GS, Slusarchyk WA, Bolton SA, Hartl KS, Jacobs G, Mathur A, Meng W, Ogletree ML, Pi Z, Sutton JC, Treuner U, Zahler R, Zhao G, Seiler SM.

Bioorg Med Chem Lett. 2004 May 3;14(9):2227-31.

PMID:
15081014
9.

Synthesis of potent and selective 2-azepanone inhibitors of human tryptase.

Zhao G, Bolton SA, Kwon C, Hartl KS, Seiler SM, Slusarchyk WA, Sutton JC, Bisacchi GS.

Bioorg Med Chem Lett. 2004 Jan 19;14(2):309-12. Erratum in: Bioorg Med Chem Lett. 2004 Feb 23;14(4):1057.

PMID:
14698147
10.

Synthesis of potent and highly selective inhibitors of human tryptase.

Slusarchyk WA, Bolton SA, Hartl KS, Huang MH, Jacobs G, Meng W, Ogletree ML, Pi Z, Schumacher WA, Seiler SM, Sutton JC, Treuner U, Zahler R, Zhao G, Bisacchi GS.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3235-8.

PMID:
12372541
11.

Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.

Sutton JC, Bolton SA, Hartl KS, Huang MH, Jacobs G, Meng W, Ogletree ML, Pi Z, Schumacher WA, Seiler SM, Slusarchyk WA, Treuner U, Zahler R, Zhao G, Bisacchi GS.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33.

PMID:
12372540
12.

Development of potent thrombin receptor antagonist peptides.

Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, Seiler SM.

J Med Chem. 1996 Dec 6;39(25):4879-87.

PMID:
8960546
13.

Non-prostanoid prostacyclin mimetics. 6. Derivatives of 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid modified beta-to the oxazole ring.

Meanwell NA, Rosenfeld MJ, Trehan AK, Wright JJ, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Gamberdella M, Hartl KS, et al.

Drug Des Discov. 1994 Jan;11(1):73-89.

PMID:
7520762
14.

Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted alpha to the oxazole ring.

Meanwell NA, Rosenfeld MJ, Wright JJ, Brassard CL, Buchanan JO, Federici ME, Fleming JS, Gamberdella M, Hartl KS, Zavoico GB, et al.

J Med Chem. 1993 Nov 26;36(24):3871-83.

PMID:
8254619
15.

Isolation and identification of lysophosphatidylcholines as endogenous modulators of thromboxane receptors.

Phillipson DW, Tymiak AA, Tuttle JG, Hartl KS, Harper TW, Bolgar MS, Allen GT, Ogletree ML.

J Lipid Mediat. 1993 Jun;7(2):155-67.

PMID:
8400117
17.

Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.

Harris DN, Michel IM, Goldenberg HJ, Hartl KS, Allen GT, Steinbacher TE, Schumacher WA, Han WC, Hall SE, Floyd DM, et al.

J Pharmacol Exp Ther. 1992 Apr;261(1):131-7.

PMID:
1532833
18.

Activity of the short-acting thromboxane receptor antagonist, SQ 30,741, in thrombolytic and vasospastic models in monkeys.

Schumacher WA, Heran CL, Hartl KS, Ogletree ML.

J Pharmacol Exp Ther. 1990 May;253(2):841-6.

PMID:
2140131

Supplemental Content

Loading ...
Support Center